Personalized neoantigen vaccine platform and longitudinal tracking of vaccine-related clonotypes enable the identification of tumor-specific TCRs
Effective immunotherapeutic strategies for high-grade serous ovarian cancer (HGSOC) remain limited despite evidence of tumor immunogenicity. Here, we report the longitudinal immune characterization of a patient with homologous recombination-deficient HGSOC treated with a personalized neoantigen-based dendritic cell...